Selective fluorescence probes for dipeptidyl peptidase activity - Fibroblast activation protein and dipeptidyl peptidase IV

Bioconjugate Chemistry

Volumn 18, Issue 4, 2007, Pages 1246-1250

  Koon, Siew Lai ^a   Ho, Nan Hui ^a   Cheng, Jonathan D ^b   Tung, Ching Hsuan ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; ENZYME ACTIVITY; FIBROBLASTS; FLUORESCENCE; PROBES; TUMORS;

CELLULAR ENVIRONMENT; CHEMO-SENSORS; DIPEPTIDYL PEPTIDASE; DIRECT READOUT; ENZYMES ACTIVITY; FLUORESCENCE PROBES; PEPTIDASE ACTIVITY; PROTEOLYTIC ACTIVITIES; SELECTIVE FLUORESCENCE; SERINE PROTEASE;

CHEMICAL ACTIVATION;

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; FIBROBLAST ACTIVATION PROTEIN; FLUORESCENT DYE; MEMBRANE ENZYME; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE; HUMAN; HUMAN CELL; METASTASIS; PROTEIN DEGRADATION; SENSOR; TUMOR GROWTH; VALIDATION PROCESS; WOUND HEALING;

EID: 34547154174     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0603586     Document Type: Article

References (26)

1. Scanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., and Rettig, W. J. (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. U.S.A. 91, 5657-5661.
2. Cheng, J. D., and Weiner, L. M. (2003) Tumors and their microenvironments: tilling the soil. Clin. Cancer Res. 9, 1590-1595.
3. Aertgeerts, K., Levin, I., Shi, L., Snell, G. P., Jennings, A., Prasad, G. S., Zhang, Y., Kraus, M. L., Salakian, S., Sridhar, V., Wijnands, R., and Tennant, M. G. (2005) Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J. Biol. Chem. 280, 19441-19444.
4. Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., and Rettig, W. J. (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 274, 36505-36512.
5. Edosada, C. Y., Quan, C., Wiesmann, C., Tran, T., Sutherlin, D., Reynolds, M., Elliott, J. M., Raab, H., Fairbrother, W., and Wolf, B. B. (2006) Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J. Biol. Chem. 281, 7437-7444.
6. Edosada, C. Y., Quan, C., Tran, T., Pham, V., Wiesmann, C., Fairbrother, W., and Wolf, B. B. (2006) Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 580, 1581-1586.
7. Garin-Chesa, P., Old, L. J., and Rettig, W. J. (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. U.S.A. 87, 7235-7239.
8. Dolznig, H., Schweifer, N., Puri, C., Kraut, N., Rettig, W. J., Kerjaschki, D., and Garin-Chesa, P. (2005) Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 5, 10.
9. Cheng, J. D., Valianou, M., Canutescu, A. A., Jaffe, E. K., Lee, H. O., Wang, H., Lai, J. H., Bachovchin, W. W., and Weiner, L. M. (2005) Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 4, 351-360.
10. Cheng, J. D., Dunbrack, R. L., Jr., Valianou, M., Rogatko, A., Alpaugh, R. K., and Weiner, L. M. (2002) Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62, 4767-4772.
11. Coutts, S. J., Kelly, T. A., Snow, R. J., Kennedy, C. A., Barton, R. W., Adams, J., Krolikowski, D. A., Freeman, D. M., Campbell, S. J., Ksiazek, J. F., and Bachovchin, W. W. (1996) Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J. Med. Chem. 39, 2087-2094.
12. Nemunaitis, J., Vukelja, S. J., Richards, D., Cunningham, C., Senzer, N., Nugent, J., Duncan, H., Jones, B., Haltom, E., and Uprichard, M. J. (2006) Phase I trial of PT-100, a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy. Cancer Invest. 24, 553-561.
13. Wesley, U. V., Tiwari, S., and Houghton, A. N. (2004) Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int. J. Cancer 109, 855-866.
14. Kelly, T. (2005) Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist. Updates 8, 51-58.
15. Gorrell, M. D. (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. 108, 277-292.
16. Miller, S., and St. Onge, E. L. (2006) Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann. Pharmacother. 40, 1336-1343.
17. Rosenblum, J. S., and Kozarich, J. W. (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol. 7, 496-504.
18. Adams, S., Miller, G. T., Jesson, M. I., Watanabe, T., Jones, B., and Wallner, B. P. (2004) PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 64, 5471-5480.
19. Hu, Y., Ma, L., Wu, M., Wong, M. S., Li, B., Corral, S., Yu, Z., Nomanbhoy, T., Alemayehu, S., Fuller, S. R., Rosenblum, J. S., Rozenkrants, N., Minimo, L. C., Ripka, W. C., Szardenings, A. K., Kozarich, J. W., and Shreder, K. R. (2005) Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7. Bioorg. Med. Chem. Lett. 15, 4239-4242.
20. Lee, J., Fassnacht, M., Nair, S., Boczkowski, D., and Gilboa, E. (2005) Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65, 11156-11163.
21. Shreder, K. R., Wong, M. S., Corral, S., Yu, Z., Winn, D. T., Wu, M., Hu, Y., Nomanbhoy, T., Alemayehu, S., Fuller, S. R., Rosenblum, J. S., and Kozarich, J. W. (2005) Boro-norleucine as a P1 residue for the design of selective and potent DPP7 inhibitors. Bioorg. Med. Chem. Lett. 15, 4256-4260.
22. Grant, S. K., Sklar, J. G., and Cummings, R. T. (2002) Development of novel assays for proteolytic enzymes using rhodamine-based fluorogenic substrates. J. Biomol. Screen 7, 531-540.
23. Ho, N. H., Weissleder, R., and Tung, C. H. (2006) Development of a dual fluorogenic and chromogenic dipeptidyl peptidase IV substrate. Bioorg. Med. Chem. Lett. 16, 2599-2602.
24. Ho, N. H., Weissleder, R., and Tung, C. H. (2006) Development of water-soluble far-red fluorogenic dyes for enzyme sensing. Tetrahedron 62, 578-585.
25. Collins, P. J., McMahon, G., O'Brien, P., and O'Connor, B. (2004) Purification, identification and characterisation of seprase from bovine semm. Int. J. Biochem. Cell Biol. 36, 2320-2333.
26. Lee, K. N., Jackson, K. W., Christiansen, V. J., Lee, C. S., Chun, J. G., and McKee, P. A. (2006) Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 107, 1397-1404.